Recently, Pfizer and SFJ Pharmaceuticals entered into a collaboration to jointly expand the lung cancer drug dacomitinib for late-stage clinical study.
dacomitinib is a pan-human epidermal growth factor receptor (pan-HER) inhibitors. The Phase Ⅲ study will be launched in Asia and many parts of Europe, the aim is to assess the dacomitinib used for local and metastatic non-small cell lung cancer immunization activities for the pan-HER role.
Pfizer Oncology Head Garry Nicholson said: "The development of inter-firm cooperation will work more efficiently, more quickly bring products to market so far, non-small cell lung cancer is still an incurable disease. "
Pfizer jointly develop a lung cancer drug SFJ
ReplyDeleteRecently, Pfizer and SFJ Pharmaceuticals entered into a collaboration to jointly expand the lung cancer drug dacomitinib for late-stage clinical study.
dacomitinib is a pan-human epidermal growth factor receptor (pan-HER) inhibitors. The Phase Ⅲ study will be launched in Asia and many parts of Europe, the aim is to assess the dacomitinib used for local and metastatic non-small cell lung cancer immunization activities for the pan-HER role.
Pfizer Oncology Head Garry Nicholson said: "The development of inter-firm cooperation will work more efficiently, more quickly bring products to market so far, non-small cell lung cancer is still an incurable disease. "
Medchemexpress Can provide the above product,its website:www.medchemexpress.com
HIV-1 integrase inhibitor
BMS-707035
Nelfinavir
Tezampanel
NS309
Vernakalant
Vernakalant Hydrochloride
Dronedarone hydrochloride
Dronedarone
Ruxolitinib